Table 1.
General characteristics of enrolled population characterized by advanced NYHA class, high congestion score, and oral diuretic administration associated with poor diuretic response.
| n = 132 Patients | GROUP F (67 pz) | GROUP M (65 pz) |
|---|---|---|
| AGE | 69 ± 16 (median 70 IQR 60–82) | 71 ± 21 (median 70 IQR 58–84) |
| GENDER | 32 F–38 M | 17 F–46 M |
| BMI (kg/m2) | 27 ± 7 (median 27 IQR 24–32) | 28 ± 6 (median 28 IQR 24–32) |
| HYPERTENSION | 55 (77%) | 46 (75%) |
| DYSLIPIDEMIA | 35 (49%) | 28 (45%) |
| DIABETES | 22 (31%) | 16 (26%) |
| CMD | 36 (51%) | 32 (51%) |
| PREVIOUS CAD | 28 (39%) | 25 (40%) |
| VALVULAR DISEASE | 7 (10%) | 3 (9%) |
| ATRIAL FIBRILLATION | 23 (32%) | 21 (33%) |
| MEAN EF (%) | 34 ± 6 | 32 ± 7 |
| PRO-BNP (pg/mL) | 10,316 ± 8815 (median 10,500 IQR 550–14,900) | 12,177 ± 6283 (median 11,200 IQR 5600–14,300) |
| CONGESTION SCORE | 3.16 ± 0.71 (median 3 IQR 2.5–3.5) | 3.08 ± 0.81 (median 3 IQR 2–3.2) |
| CREATININE ADMISSION (mg/dL) | 1.76 ± 1.05 (median 1.8 IQR 1.3–2.1) | 1.67 ± 1.2 (median 1.6 IQR 1.3–2.1) |
| eGFR (mL/min) | 39.3 ± 18 (median 38 IQR 25–45) | 40.5 ± 20 (median 40 IQR 22–55) |
| CKD | 35 (57%) | 32 (51%) |
| Blood UREA (mg/dL) | 80 ± 31 (median 78 IQR 50–75) | 66 ± 17 (median 68 IQR 48–70) |
| K (mEq/L) | 4.3 ± 0.5 (median 4.2 IQR 4–4.5) | 4.1 ± 0.8 (median 4.1 IQR 3.6–4.4) |
| Na (mEq/L) | 136 ± 5 (median 137 IQR 133–141) | 137 ± 5 (median 138 IQR 136–140) |
| BLOOD PRESSURE (mmHg) | SYS 145 ± 20 DIA 81 ± 15 |
SYS 138 ± 18 DIA 75 ± 15 |
| NYHA class | CLASS III = 17 pz (28%) CLASS IV = 51 pz (72%) |
CLASS III = 15 pz (27%) CLASS IV = 50 pz (73%) |
| Loop diuretic dose at admission (mg/day) | 230 ± 150 (median 225 IQR 120–300) | 250 ± 120 (median 230 IQR 125–350) |
| ACE-Inhibitors | 39 (58%) | 36 (55%) |
| Angiotensin receptor Blocker (ARB) | 20 (30%) | 20 (31%) |
| Beta-blockers | 41 (61%) | 43 (66%) |
| Digoxin | 20 (30%) | 17 (26%) |
| Mineralocorticoid antagonists (MRA) | 28 (42%) | 26 (40%) |
| Angiotensin receptor–neprilysin inhibitors (ARNIs) | 8 (12%) | 9 (14%) |